AI healthcare company Acreal (CEO Seunghyun Jeon) announced on the 16th that it has secured a total of 8 billion won in pre-Series A investment from DSC Investment, SDB Investment, Schmidt, and Suin Investment Capital. This investment brings the total investment to 14.1 billion won, demonstrating recognition of Acreal's unique technological prowess and global expansion potential.
Arcreal developed the intraoral scanner, "ArcScan," using proprietary technology. It boasts performance comparable to premium global products and a competitive price. ArcScan has secured key medical device approvals, including the US FDA and the European CE MDR, laying the foundation for global commercialization. The company plans to accelerate sales by expanding global sales agreements starting later this year.
Oral scanners are a key data acquisition device for dental AI services. Most services, including AI diagnosis, CAD design, treatment planning, and prosthetic fabrication, rely on scanner data. Accordingly, oral scanner companies are expected to dominate the global dental market in the AI platform race.
Arkreal has a full-stack structure, developing all aspects in-house, from software engines and AI models to platforms and hardware design and manufacturing. CEO Jeon Seung-hyun and CTO Kim Kyung-guk lead technology development, while Professor Shin Jin-woo of the KAIST AI Graduate School oversees AI research.
Professor Shin Jin-woo said, “Acrial has established a foundation for directly obtaining precise 3D oral data, and based on this, we are increasing the completion rate of the 3D image foundation model specialized in oral structure.”
SDB Investment Managing Director Kim Jeong-hoon said, “We highly value the Acrial team’s technological prowess and execution capabilities, and the continued participation of existing investors demonstrates this,” adding, “Starting with the oral scanner, we will lead the global digital dentistry innovation.”
- See more related articles
You must be logged in to post a comment.